• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Port Info

• Ships in Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• The Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad , July 14

AUROBINDO Pharma Ltd has obtained the Canadian regulatory authority's compliance for unit-III for oral solid dosage forms and unit-VI for sterile and non-sterile cephalosporin dosage forms. Health Canada has approved these sites, the company said in a press release here. The company said the unit-III, located at Hyderabad, was one of its key formulation manufacturing facilities. It had four production blocks and was dedicated to products other than cephalosporins/penicillin's oral dosage formulations. The unit was also approved by the USFDA, South African MCC, Brazilian ANVISA and UK MHRA (previously known as UK MCA). In addition, it held ISO and approvals from several other countries, the company said.

The unit-VI is situated in an 18-acre area and comprises five manufacturing blocks. It is into oral dosage formulations and has also got approvals from all these regulatory agencies apart from the Canadian authority. The unit is located near Hyderabad, according to the release.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Dr Reddy's launches Colostrum in tie-up with New Zealand co

Copyright © 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line